Telehealth to Address Vaccine Hesitancy

Sponsor
Xavier University of Louisiana. (Other)
Overall Status
Not yet recruiting
CT.gov ID
NCT05676970
Collaborator
(none)
525
1
2
60
8.8

Study Details

Study Description

Brief Summary

This study is a 24-30 month behavioral intervention study to assess the impact of enrolling individuals a clinical pharmacist run telehealth education focused on wellness and vaccination. Individuals will be randomized to either a wellness only model focusing on nutrition, diabetes and hypertension or a wellness model with a vaccination education component. All participants will complete individual and group based interventions. Individuals will be recruited from industries with high risk for COVID-19 and other respiratory illness infection, such as health workers, teachers aides and the food industry. We are recruiting individuals who identify as African-American, Hispanic, come from a semi-rural/rural community or have additional social determinants of health that indicate social vulnerability. The primary outcome is COVID-19 vaccine completion. The secondary outcome is influenza vaccine completion.

Condition or Disease Intervention/Treatment Phase
  • Behavioral: Telehealth: Wellness and Vaccination
  • Behavioral: TeleHealth: Wellness Only
N/A

Detailed Description

Individuals will be recruited using a community-based participatory research model to identify 525 patients to enter into an 24-30 month clinical pharmacist run, vaccine and health and wellness program delivered via Xavier's clinical pharmacy faculty trained in telehealth medicine using an individually randomized group treatment trial approach based upon industry of recruitment. Our recruitment will target enrollment of: 65% African-Americans, 10% Hispanic and 20% rural, with overlapping categories as necessary.

Participants will be recruited from target high risk industries for COVID-19 infection:

hospitality and food industry, plant workers, nurse's aides, teacher's aides and the beauty industries. Participants will complete a minimum of three individual visits and group informational visits. Both arms of the study will receive health and wellness visits. Only the vaccine intervention arm will receive the vaccine and counseling. Changes in vaccine hesitancy and monitoring for vaccine completion will occur by the clinical pharmacist via patient interviews and LinksĀ© access. The primary outcome will be completed COVID-19 vaccination series (primary series + applicable boosters). The secondary outcome will be completed influenza vaccine.

Impact: The implications of this proposed project are to understand health related beliefs and behaviors related to vaccination and vaccine hesitancy in the context of a general health and wellness model. This intervention approach aims to decrease vaccine disparities among vulnerable individuals. It will provide data to develop strategies to improve vaccination, especially COVID-19 vaccination, in vulnerable communities using pharmacy students and pharmacists. This grant will facilitate training early stage investigators and diversify the health research workforce as the researchers are underrepresented minorities and women.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
525 participants
Allocation:
Non-Randomized
Intervention Model:
Parallel Assignment
Intervention Model Description:
We propose to use a individually randomized group treatment trial design with a baseline survey to assess social determinants of health, COVID-19 experience and knowledge, baseline demographic information and vaccine hesitancy as relates to potential COVID-19 vaccine uptake in our target population. We will then randomize participants in a 1:1 fashion to a vaccine intervention arm and a control arm matched baseline vaccine hesitancy score. Given this is an IRGT (Individualized Randomized Group Treatment) trial design, a priori matching should assist in preventing a Type I error. Individuals will then complete 8 individual or group based behavioral health interventions via a Telehealth model conducted by a Clinical Pharmacist.We propose to use a individually randomized group treatment trial design with a baseline survey to assess social determinants of health, COVID-19 experience and knowledge, baseline demographic information and vaccine hesitancy as relates to potential COVID-19 vaccine uptake in our target population. We will then randomize participants in a 1:1 fashion to a vaccine intervention arm and a control arm matched baseline vaccine hesitancy score. Given this is an IRGT (Individualized Randomized Group Treatment) trial design, a priori matching should assist in preventing a Type I error. Individuals will then complete 8 individual or group based behavioral health interventions via a Telehealth model conducted by a Clinical Pharmacist.
Masking:
None (Open Label)
Primary Purpose:
Prevention
Official Title:
Using a Telehealth Model to Address Vaccine Hesitancy and Increase Vaccine Completion Among Vulnerable Communities in Southeastern Louisiana
Anticipated Study Start Date :
Jan 1, 2024
Anticipated Primary Completion Date :
Dec 1, 2028
Anticipated Study Completion Date :
Dec 30, 2028

Arms and Interventions

Arm Intervention/Treatment
Experimental: Telehealth Arm: Wellness with Vaccine Education

Individuals in this arm will complete standardized telehealth interventions that focus on nutrition, work-life balance, mental health, diabetes and hypertension. In addition, they will complete education and counseling on vaccination. All educations will be completed one-on-one as well as small group.

Behavioral: Telehealth: Wellness and Vaccination
Individuals in this arm will complete standardized telehealth interventions that focus on nutrition, work-life balance, mental health, diabetes and hypertension. In addition, they will complete education and counseling on vaccination. All educations will be completed one-on-one as well as small group.

Active Comparator: Telehealth Arm: Wellness Only

Individuals in this arm will complete standardized telehealth interventions that focus on nutrition, work-life balance, mental health, diabetes and hypertension. All educations will be completed one-on-one as well as small group.

Behavioral: TeleHealth: Wellness Only
Individuals in this arm will complete standardized telehealth interventions that focus on nutrition, work-life balance, mental health, diabetes and hypertension. All educations will be completed one-on-one as well as small group.

Outcome Measures

Primary Outcome Measures

  1. COVID-19 Vaccine Series Completion [1 year]

    Questionnaire derived from Documented completion in immunization health record of primary COVID-19 vaccine series + COVID-19 Booster (Binary: Completed or not completed)

  2. COVID-19 Vaccine Series Completion [Through study completion, on average, two years]

    Questionnaire derived from Documented completion in immunization health record of primary COVID-19 vaccine series + COVID-19 Booster (Binary: Completed or not completed)

Secondary Outcome Measures

  1. Influenza Vaccination Completion [1 year]

    Questionnaire derived from Documented completion in immunization health record of annual influenza vaccine (per vaccine year)

  2. Influenza Vaccination Completion [Through study completion, on average, two years]

    Questionnaire derived from Documented completion in immunization health record of annual influenza vaccine (Binary: Completed or not completed)

  3. Vaccine Hesitancy Scale [1 year]

    Ordinal Scale rom 1 to 5 (5 Most Hesitant, 1 Least Hesitant) of Likelihood to Complete COVID-19 vaccine and influenza vaccine (Binary: Completed or not completed)

  4. Vaccine Hesitancy Scale [Through study completion, on average, two years]

    Ordinal Scale rom 1 to 5 (5 Most Hesitant, 1 Least Hesitant) of Likelihood to Complete COVID-19 vaccine and influenza vaccine

  5. Change in Vaccine Hesitancy Scale [Through study completion, on average, two years]

    Change from Baseline to Study Completion Ordinal Scale rom 1 to 5 (5 Most Hesitant, 1 Least Hesitant) of Likelihood to Complete COVID-19 vaccine and influenza vaccine

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years to 55 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
Yes
Inclusion Criteria:
  1. Incomplete vaccination defined as 1a. Incomplete COVID-19 vaccine series 1b. Incomplete COVID-19 booster 1c. Incomplete annual influenza

  2. Adults aged 18 years to 55 years of age

  3. Able to speak English

  4. Currently employed or seeking training in target industries such as: healthcare, education, beauty, hospitality, food (culinary) and industrial plant workers.

  5. Able to use Telehealth technology via tablet, cell phone, or computer

Exclusion Criteria:
  1. Individuals who have completed the COVID-19 vaccine series and boosters.

  2. Individuals with documented allergy or reaction to COVID-19 or influenza vaccine

  3. Individuals who are unable to give informed consent.

  4. Individuals with diagnosis of immunosuppressive conditions such as cancer, lupus, rheumatoid arthritis, Crohn's disease, Ulcerative Colitis, primary immunodeficiency, or organ transplant recipients

  5. Individuals diagnoses with congestive heart failure

  6. Individuals diagnosed with any cardiac arrhythmia

Contacts and Locations

Locations

Site City State Country Postal Code
1 Xavier University of Louisiana New Orleans Louisiana United States 70125

Sponsors and Collaborators

  • Xavier University of Louisiana.

Investigators

  • Principal Investigator: Klaus Heyer, PhD, Nunez Community College

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Sara Al-Dahir, Clinical Professor, Xavier University of Louisiana.
ClinicalTrials.gov Identifier:
NCT05676970
Other Study ID Numbers:
  • SA003
First Posted:
Jan 9, 2023
Last Update Posted:
Jan 9, 2023
Last Verified:
Dec 1, 2022
Individual Participant Data (IPD) Sharing Statement:
Yes
Plan to Share IPD:
Yes
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Sara Al-Dahir, Clinical Professor, Xavier University of Louisiana.

Study Results

No Results Posted as of Jan 9, 2023